Provided by Tiger Fintech (Singapore) Pte. Ltd.

Novo-Nordisk A/S

69.23
+3.635.53%
Post-market: 69.350.1200+0.17%16:14 EDT
Volume:13.43M
Turnover:928.81M
Market Cap:307.32B
PE:22.04
High:69.86
Open:69.75
Low:68.53
Close:65.60
Loading ...

Is Novo Nordisk A/S (NVO) The Top Falling Stock with Unusual Volume?

Insider Monkey
·
22 Apr

Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note

Zacks
·
22 Apr

Novo submits obesity pill for FDA approval, BioPharma Dive reports

TIPRANKS
·
22 Apr

LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study

Zacks
·
21 Apr

Wall Street Trims Ratings for Novo Nordisk Stock, as Ozempic's Competition Grows -- Barrons.com

Dow Jones
·
19 Apr

Novo Nordisk downgraded to Neutral from Buy at Guggenheim

TIPRANKS
·
18 Apr

Novo Nordisk downgraded by BMO as Eli Lilly gains ground in weight-loss drug race

Investing.com
·
18 Apr

Jefferies Sticks to Its Sell Rating for Novo Nordisk (0QIU)

TIPRANKS
·
18 Apr

J.P. Morgan Sticks to Its Buy Rating for Novo Nordisk (0QIU)

TIPRANKS
·
18 Apr

Novo Nordisk's ADRs Slide After Eli Lilly Obesity Pill Results -- Market Talk

Dow Jones
·
17 Apr

Eli Lilly's weight loss pill could be just as good as Ozempic — and the stock soars

Quartz
·
17 Apr

European Equities Traded in the US as American Depositary Receipts Modestly Higher in Thursday Trading

MT Newswires Live
·
17 Apr

Stock Track | Novo Nordisk Plummets 8% Pre-market on Analyst Downgrade and Rival's Breakthrough in Weight Loss Market

Stock Track
·
17 Apr

Stock Track | Novo Nordisk Plummets 8.08% as Analyst Downgrades and Rival's Breakthrough Shake Investor Confidence

Stock Track
·
17 Apr

Eli Lilly Shares Soar 14% as Lilly Pill Leads To 7.9% Weight Loss In Late-Stage Trial

Reuters
·
17 Apr

Stock Track | Novo Nordisk Plunges 7.57% Pre-market on Analyst Downgrade and Rival's Breakthrough

Stock Track
·
17 Apr

BMO Capital Downgrades Novo Nordisk to Market Perform From Outperform, Adjusts Price Target to $64 From $105

MT Newswires Live
·
17 Apr

Novo Nordisk Cut to Market Perform From Outperform by BMO Capital

Dow Jones
·
17 Apr

Novo Nordisk : Bmo Cuts to Market Perform From Outperform; Cuts Target Price to $64 From $105

THOMSON REUTERS
·
17 Apr

Eli Lilly's Mounjaro Launch Triggers Weight-Loss Drug Craze In India, Novo Nordisk Seeks To Move Up Wegovy Launch

Benzinga
·
17 Apr